Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Enterprise Value of -$170.4 million for Q1 2026, down 82.84% year-over-year from -$992.7 million in Q1 2025, and up 4.7% quarter-over-quarter from -$178.8 million in Q4 2025.
Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Enterprise Value for 7 consecutive years, with -$170.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 82.84% year-over-year to -$170.4 million; the TTM figure through Mar 2026 stood at -$170.4 million (down 82.84% YoY), while the FY2025 annual figure was -$178.8 million, down 83.27% from the prior year.
- Enterprise Value grew to -$170.4 million in Q1 2026 per IKT's latest filing, from -$178.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$3.2 million in Q3 2024 and bottomed at -$178.8 million in Q4 2025.
- Historically, Enterprise Value has averaged -$54.2 million across 5 years, with a median of -$26.5 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 80.73% — and 2025, when it tumbled 2283.81%.
- Inhibikase Therapeutics' Enterprise Value stood at -$23.1 million in 2022, then soared by 42.51% to -$13.3 million in 2023, then sank by 636.06% to -$97.5 million in 2024, then tumbled by 83.27% to -$178.8 million in 2025, then grew by 4.7% to -$170.4 million in 2026.
- Business Quant data shows IKT's Enterprise Value at -$170.4 million in Q1 2026, -$178.8 million in Q4 2025, and -$77.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -159.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -159.02 Mn |
| Mar 31, 2026 | -170.37 Mn |
| Dec 31, 2025 | -178.76 Mn |
| Sep 30, 2025 | -77.32 Mn |
| Jun 30, 2025 | -87.67 Mn |
| Mar 31, 2025 | -93.18 Mn |
| Dec 31, 2024 | -97.54 Mn |
| Sep 30, 2024 | -3.24 Mn |
| Jun 30, 2024 | -7.94 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -13.25 Mn |
| Sep 30, 2023 | -16.83 Mn |
| Jun 30, 2023 | -20.94 Mn |
| Mar 31, 2023 | -25.72 Mn |
| Dec 31, 2022 | -23.05 Mn |
| Sep 30, 2022 | -26.53 Mn |
| Jun 30, 2022 | -32.21 Mn |
| Mar 31, 2022 | -36.61 Mn |
| Dec 31, 2021 | -40.75 Mn |
| Sep 30, 2021 | -44.85 Mn |